Evidence map›Paper›PMID 41226589›Full record

ArticleInternational journal of molecular sciences2025

A Novel Germline Frameshift Variant in the Tumor Suppressor Gene

Barbara Anna Bokor, Aliasgari Abdolreza, Margit Pál, Zita Battyani, Márta Széll, Nikoletta Nagy

Abstract readCase Reports
In one paragraph

Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Barbara Anna BokorDepartment of Medical Genetics, University of Szeged, 6720 Szeged, Hungary.ORCID 0009-0002-0824-1047
Aliasgari AbdolrezaDepartment of Medical Genetics, University of Szeged, 6720 Szeged, Hungary.
Margit PálDepartment of Medical Genetics, University of Szeged, 6720 Szeged, Hungary.ORCID 0000-0003-3662-0837
Zita BattyaniMór Kaposi Teaching Hospital, 7400 Kaposvár, Hungary.ORCID 0000-0002-5570-6831
Márta SzéllDepartment of Medical Genetics, University of Szeged, 6720 Szeged, Hungary.ORCID 0000-0002-0730-714X
Nikoletta NagyDepartment of Medical Genetics, University of Szeged, 6720 Szeged, Hungary.ORCID 0000-0001-8576-7953

Funding

Government of Hungary EFOP-3.6.1-16-2016-00008Government of Hungary GINOP-2.3.2-15-2016-00039
6 · The paper itself

Abstract

Malignant melanoma is a complex malignancy with genetic, environmental, and lifestyle factors in its etiology. While germline variants in melanoma predisposition genes have been described, many patients remain genetically unexplained after panel testing. We previously analyzed a Hungarian melanoma cohort (n = 17), identifying variants in predisposing or susceptibility genes in 58.82% of patients. For individuals negative on this melanoma-specific panel, we expanded testing to a 19-gene panel associated with multiple cancer types. Next-generation sequencing was performed, followed by Sanger sequencing for confirmation. Variants were classified according to ACMG guidelines. In a 58-year-old female patient with a history of primary cutaneous melanoma, we identified a novel heterozygous frameshift variant in the tumor suppressor gene

Indexed as

Frameshift MutationGenes, Tumor SuppressorGerm-Line MutationMelanomaSkin NeoplasmsFemaleGenetic Predisposition to DiseaseHumansMiddle Agedcancer predispositiongermline variantmelanomanext-generation sequencingOBSCN

Identifiers

PMID41226589
PMCPMC12609535

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.